Literature DB >> 19666655

Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.

Stefanie Strobel1, Peter F Hoyer, Christoph J Mache, Endre Sulyok, Wei-Shih Liu, Heiko Richter, Martin Oppermann, Peter F Zipfel, Mihály Józsi.   

Abstract

BACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) is associated with defective complement regulation. Recently, an autoimmune aHUS form has been described that is associated with complement factor H (CFH) autoantibodies. The aim of this study was to address the pathologic relevance of CFH autoantibodies in aHUS.
METHODS: CFH autoantibodies were identified and antibody levels were analysed in three aHUS patients during the disease course by the ELISA method. Epitope mapping was performed using recombinant factor H fragments and domain-mapped monoclonal antibodies. The effect of the antibodies on cell-protective activity of CFH was measured by haemolytic assays. CFH:autoantibody complexes were analysed by ELISA.
RESULTS: All three autoantibodies bound to the C-terminal domain of CFH, which is essential for CFH binding to cell surfaces. In patient 1, plasma exchanges and immune adsorption temporarily reduced the autoantibody titre and led to temporary clinical improvement. In patient 2, plasma exchanges and long-term immunosuppression strongly reduced the CFH autoantibody level, and induced a stable remission of aHUS. Patient 3 had lower autoantibody levels that decreased during the follow-up and is in good clinical condition. The patients' plasma samples caused enhanced lysis of sheep erythrocytes, and the degree of lysis correlated with the CFH autoantibody titre and the amount of CFH:autoantibody complexes. An addition of purified CFH to aHUS plasma or removal of IgG inhibited the haemolytic activity.
CONCLUSION: These results support a direct role of the autoantibodies in aHUS pathology by inhibiting the regulatory function of CFH at cell surfaces and suggest that reduction of the autoantibody titre is beneficial for the patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666655     DOI: 10.1093/ndt/gfp388

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  32 in total

Review 1.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

2.  Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Sidharth Kumar Sethi; Arvind Bagga; Caroline Blanc; Jacques Blouin; Bruno Ranchin; Jean-Luc André; Nobuaki Takagi; Hae Il Cheong; Pankaj Hari; Moglie Le Quintrec; Patrick Niaudet; Chantal Loirat; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 10.121

3.  Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome.

Authors:  Wei-Yi Guo; Di Song; Xiao-Rong Liu; Zhi Chen; Hui-Jie Xiao; Jie Ding; Shu-Zhen Sun; Hong-Yan Liu; Su-Xia Wang; Feng Yu; Ming-Hui Zhao
Journal:  Pediatr Nephrol       Date:  2018-10-12       Impact factor: 3.714

4.  The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome.

Authors:  Di Song; Xiao-Rong Liu; Zhi Chen; Hui-Jie Xiao; Jie Ding; Shu-Zhen Sun; Hong-Yan Liu; Wei-Yi Guo; Su-Xia Wang; Feng Yu; Ming-Hui Zhao
Journal:  Pediatr Nephrol       Date:  2016-12-29       Impact factor: 3.714

5.  Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.

Authors:  Johannes Hofer; Andreas R Janecke; L B Zimmerhackl; Magdalena Riedl; Alejandra Rosales; Thomas Giner; Gerard Cortina; Carola J Haindl; Barbara Petzelberger; Miriam Pawlik; Verena Jeller; Udo Vester; Bettina Gadner; Michael van Husen; Michael L Moritz; Reinhard Würzner; Therese Jungraithmayr
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

Review 6.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 7.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

8.  Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.

Authors:  Gwenaëlle Sana; Marie-Agnès Dragon-Durey; Marina Charbit; Karim Bouchireb; Caroline Rousset-Rouvière; Etienne Bérard; Rémi Salomon; Véronique Frémeaux-Bacchi; Patrick Niaudet; Olivia Boyer
Journal:  Pediatr Nephrol       Date:  2013-07-19       Impact factor: 3.714

Review 9.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

10.  Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

Authors:  Serena Giuntini; Peter T Beernink; Dan M Granoff
Journal:  Vaccine       Date:  2015-11-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.